Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Ability

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44258   clinical trials with a EudraCT protocol, of which   7344   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    4,879 result(s) found for: Ability. Displaying page 1 of 244.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2017-004087-35 Sponsor Protocol Number: AVXS-101-CL-304 Start Date*: 2018-12-21
    Sponsor Name:AveXis, Inc.
    Full Title: A Global Study of a Single, One-Time Dose of AVXS-101 Delivered to Infants with Genetically Diagnosed and Pre-symptomatic Spinal Muscular Atrophy with Multiple Copies of SMN2
    Medical condition: Spinal Muscular Atrophy
    Disease:
    Population Age: Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) IT (Completed) GB (GB - no longer in EU/EEA) BE (Completed) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-003268-19 Sponsor Protocol Number: BR-TUM-ICG-IV-2 Start Date*: 2014-10-06
    Sponsor Name:Jules Bordet Institute
    Full Title: Study evaluating breast cancer tumorectomy guided by Near-Infrared imaging after the intravenous injection of free Indocyanine Green
    Medical condition: Imaging of tumours and their margins after intravenous injection of Indocyanine Green to breast cancer patients
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000755-97 Sponsor Protocol Number: EPFL-CNBI-2017-01 Start Date*: 2017-03-16
    Sponsor Name:Defitech Chair in Brain-Machine Interface, EPFL
    Full Title: Brain-computer interface and neuromuscular stimulation for rehabilitation following chronic stroke
    Medical condition: I61 - Intracerebral haemorrhage I63 - Cerebral infarction Chronic condition (at least 10 months after occurrence of cerebrovascular accident)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2014-003512-37 Sponsor Protocol Number: OC-AP-ICG-IV-2 Start Date*: 2014-10-13
    Sponsor Name:Jules Bordet Institute
    Full Title: Study of the (intravenously injected) ICG (Indocyanine Green) imaging of tumoral implants in patients with peritoneal carcinomatosis from colorectal origin.
    Medical condition: Imaging of tumours and their metastasis after intravenous injection of Indocyanine Green to patients with peritoneal carcinomatosis from colorectal cancer.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-022085-26 Sponsor Protocol Number: rhLAMAN-03 Start Date*: 2010-10-05
    Sponsor Name:Zymenex A/S
    Full Title: A single center, randomized, open-label, multiple-dose study of the efficacy and long-term safety of rhLAMAN (recombinant human alpha-mannosidase or Lamazym) for the treatment of patients with alph...
    Medical condition: Treatment of alpha-Mannosidosis
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2010-022084-36 Sponsor Protocol Number: rhLAMAN-02 Start Date*: 2010-10-05
    Sponsor Name:Zymenex A/S
    Full Title: A single center, open-label, dose escalation study of the safety and pharmacokinetics of rhLAMAN (recombinant human alpha-mannosidase or Lamazym) for the treatment of patients with alpha-mannosidosis.
    Medical condition: Treatment of alpha-Mannosidosis
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2021-000070-29 Sponsor Protocol Number: 74668 Start Date*: 2022-09-15
    Sponsor Name:VU University Medical Center
    Full Title: A Proof-of-Concept Study to Explore the Potential Efficacy of Deferiprone in Patients With Pelizaeus-Merzbacher disease (PMD)
    Medical condition: Pelizaeus-Merzbacher disease
    Disease:
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-000095-38 Sponsor Protocol Number: AVXS-101-CL-303 Start Date*: 2020-03-18
    Sponsor Name:AveXis, Inc.
    Full Title: Phase 3, Open-Label, Single-Arm, Single-Dose Gene Replacement Therapy Clinical Trial for Patients with Spinal Muscular Atrophy Type 1 with One or Two SMN2 Copies Delivering AVXS-101 by Intravenous ...
    Medical condition: Gene Replacement Therapy Clinical Trial for Patients with Spinal Muscular Atrophy Type 1
    Disease:
    Population Age: Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-002368-42 Sponsor Protocol Number: LUM-001 Start Date*: 2017-10-12
    Sponsor Name:Lument AB
    Full Title: An open, randomized, controlled, single centre trial to evaluate CT image quality and diagnostic feasibility of Lumentin® 44, a new egg albumen based oral bowel filling agent, in comparison with di...
    Medical condition: None. Lumentin 44 is a contrast agent and the contrast properties will be investigated in this trial. Patients referred to computerised tomography of the abdomen will be included in the trial. Nei...
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004848 10011603 CT scan LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-000529-20 Sponsor Protocol Number: FENHYDPAI4012 Start Date*: 2008-05-20
    Sponsor Name:Janssen-Cilag Limited
    Full Title: Comparison of Ionsys® and routine care with morphine IV PCA in the management of early post-operative mobilisation, ability to mobilise and in time to Fitness For Discharge (FFD)
    Medical condition: Evaluation of the mobilisation characteristics, clinical use, safety and Ease of Care (EOC) of a Fentanyl Iontophoretic Transdermal PCA system (Ionsys) and morphine IV PCA for management of acute...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-002227-96 Sponsor Protocol Number: 1 Start Date*: 2014-09-17
    Sponsor Name:County Council of Östergötland
    Full Title: Inhibition of platelet aggregation after administration of three different ticagrelor loading dose formulations in patients with stable angina referred for coronary angiography
    Medical condition: Effect of three ticagrelor loading dose formulations on the degree and rapidity of platelet aggregation in patients with stable angina referred for coronary angiography
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-003299-22 Sponsor Protocol Number: BILA-3514/SCA Start Date*: 2014-11-18
    Sponsor Name:TNO.Netherlands Organization for Applied Scientific Research
    Full Title: Effects of Single Dose of Bilastine 20mg on Flying Ability in Healthy Volunteers Under Conditions of Simulated Cabin Pressure
    Medical condition: Healthy volunteers
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-005708-18 Sponsor Protocol Number: 14081962 Start Date*: 2010-06-04
    Sponsor Name:Queen Mary University of London
    Full Title: Prevention of metabolic complications of glucocorticoid excess
    Medical condition: Rheumatoid arthritis, SLE, Polymyalgia rheumatica, Disthyroid eye disease, Cushing's syndrome
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-003128-22 Sponsor Protocol Number: 1.1 Start Date*: 2017-10-19
    Sponsor Name:The University of Leeds
    Full Title: Intraoperative imaging of colon cancer using a fluorescent peptide (EMI-137) against the c-Met receptor
    Medical condition: Colon cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-003945-40 Sponsor Protocol Number: EPU-P112 Start Date*: 2019-04-10
    Sponsor Name:Maastricht University
    Full Title: EFFECTS OF VAPORISED CANNABIS, WITH AND WITHOUT CBD, ON DRIVING AND COGNITION
    Medical condition: This study will look at the differential effects of variations in cannabis chemovars on driving ability and cognition
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-006166-42 Sponsor Protocol Number: RIVA Start Date*: 2007-07-17
    Sponsor Name:University of Tuebingen
    Full Title: Exelon bei dementiellem Syndrom bei Patienten mit Progressiver Supranukleärer Parese - offene, prospektive Phase II-Studie -
    Medical condition: Progressive supranuclear palsy (PSP) is a neurodegenerative disorder with hardly any therapeutical option to ameliorate the course of the disease. Results of first trials with physostigmine and don...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-003678-28 Sponsor Protocol Number: AVXS-101-CL-102 Start Date*: 2020-09-15
    Sponsor Name:AveXis, Inc.
    Full Title: Phase I, Open-Label, Dose Comparison Study of AVXS-101 for Sitting but Non- Ambulatory Patients with Spinal Muscular Atrophy
    Medical condition: Gene Replacement Therapy Clinical Trial for Patients with Spinal Muscular Atrophy
    Disease:
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2005-003249-15 Sponsor Protocol Number: E-BRO-3 Start Date*: 2005-09-26
    Sponsor Name:BIONORICA AG
    Full Title: Efficacy and tolerability of Bronchipret® Saft for the treatment of acute bronchitis in adults A randomized, double-blind, placebo-controlled, parallel-group, multicenter Phase IV study.
    Medical condition: Acute bronchitis with productive cough i.e. onset of bronchial mucus production with impaired ability to cough up.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2022-001522-30 Sponsor Protocol Number: RIMOFATSCI-2 Start Date*: 2022-10-03
    Sponsor Name:Fundación Hospital Nacional de Parapléjicos
    Full Title: Effects of a CB1 receptor reverse antagonist/agonist (Rimonabant) on wandering ability in patients with incomplete spinal cord injuries
    Medical condition: Possibility of improving wandering in patients. The effects of Rimonabant on other functional measures will be assessed and it will be confirmed that it is a safe treatment in the study population.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-000371-18 Sponsor Protocol Number: 220105 Start Date*: 2005-09-23
    Sponsor Name:Portsmouth Hospitals Trust
    Full Title: The use of Thalidomide as a treatment for the cachexia of incurable upper gastrointestinal adenocarcinomas:a randomised, double-blinded, placebo controlled trial.
    Medical condition: The cachexia associated with terminal gastrointestinal adenocarcinomas
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA